Key facts
- CellVax Therapeutics’s last known valuation is $52.5M.
- It has raised $7.3M across 1 recorded rounds; the latest was Seed Round ($2.1M) in Sep 2024.
- CellVax Therapeutics has filed 1 Form D with the SEC, most recently Oct 2024 ($2.1M sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·Watchlist + deal alerts for CellVax Therapeutics
Funding rounds
1 roundsAbout CellVax Therapeutics
Developer of cell-based immunotherapies designed to recognize the abnormality of tumor cells. The company develops novel personalized immunotherapy for an anti-cancer vaccine to be used in prostate cancer patients with a risk of recurrence after prostatectomy, and is developed through cancer cells to create specific tumor-presenting cells, enabling medical practitioners to treat prostate cancer effectively and generate a strong immune response in patients.
- Sector
- Healthcare
- HQ
- Miami, FL, United States
- Founded
- 2001
- Employees
- 2
- Website
- cellvx.com/
- Ownership
- Privately Held (backing)
CellVax Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CellVax Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CellVax Therapeutics in its N-PORT filings yet. We sweep new filings monthly.